Swedish Orphan Biovitrum AB (publ)
BIOVF News Today: Stay Updated with the Latest Swedish Orphan Biovitrum AB (publ) News in Real Time
Find BIOVF news now at Meyka AI. Stay informed with the latest Swedish Orphan Biovitrum AB (publ) stocks updates, including price news, market analysis, and expert insights.
IMMP stock surges 97% on FDA orphan drug designation for efti
IMMP stock jumps 97% after FDA grants orphan drug designation for eftilagimod alfa in soft tissue sarcoma treatment.
ERCB.DE Stock Rises 0.1% as Ericsson Prepares April 17 Earnings
ERCB.DE stock at €10.2 on XETRA. Telefonaktiebolaget LM Ericsson earnings announcement April 17. Meyka AI rates B+.
EQBBF Downgraded to Neutral from Buy at Citigroup April 2026
Citigroup downgraded EQBBF from Buy to Neutral on April 13, 2026, signaling reduced confidence in EQT AB (publ).
SVNLY Analyst Rating Maintained at Hold by Deutsche Bank April 2026
Deutsche Bank maintains Hold rating on SVNLY, raises price target to SEK 135 on April 13, 2026.
SVKEF Analyst Rating Maintained at Hold by Deutsche Bank April 2026
Deutsche Bank maintains Hold rating on SVKEF, raises price target to SEK 190 on April 13, 2026.
SSAAY Maintained at Hold by Deutsche Bank April 2026
Deutsche Bank maintains SSAAY at Hold with price target raised to SEK 72 on April 13, 2026
HXGBY Maintained at Hold by Deutsche Bank, April 2026
Deutsche Bank maintains Hold rating on HXGBY, lowers price target to SEK 100 from SEK 110 on April 13, 2026.
XVIPY Xvivo Perfusion PNK $6.54 08 Apr 2026: Oversold bounce may reach $9.58
XVIPY stock update: $6.54, oversold-bounce setup with Meyka AI forecast to $9.58 and 46.48% upside
Sweden to spend $916 million on air defence systems; 8.7 billion crowns deal announced
Sweden has taken a bold step to strengthen its military defence. The government approved a deal worth 8.7 billion Swedish crowns (about $916 million) to buy new air defence and anti‑drone systems. This decision comes as global security threats grow, especially in Europe. We from this region and around the world see this investment as part of…